Lineage Cell Therapeutics (LCTX) director receives 125,000 stock options at $1.30

Rhea-AI Filing Summary

Lineage Cell Therapeutics director Russell Angus received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036.

According to the footnote, the options will vest and become exercisable on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual meeting of shareholders, in each case only if he continues to serve with the company. After this grant, his reported derivative holdings from this award total 125,000 options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Russell Angus C.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 125,000 options Exercise price: $1.30 per share Expiration date: July 1, 2036 +2 more

5 metrics

Stock options granted 125,000 options Grant to director Russell Angus

Exercise price $1.30 per share Exercise price of granted options

Expiration date July 1, 2036 Option expiration for this grant

Underlying shares 125,000 common shares Shares underlying granted options

Vesting trigger date July 1, 2027 or next annual meeting Earlier of these dates, subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Shares"

continuous service financial

"subject in any case to the reporting person's continuous service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:02 PM Accepted by SEC EDGAR 07/02/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Angus C.

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	Common Shares	125,000	$0.00	125,000	D

Explanation of Responses:

1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

	/s/ Alexandra Hernandez, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lineage Cell Therapeutics (LCTX) director Russell Angus report in this Form 4?

He reported receiving a stock option grant for 125,000 common shares. The options are a compensation-related award, not an open-market trade, and were granted with specific vesting, exercise price, and expiration terms set by Lineage Cell Therapeutics.

What are the key terms of Russell Angus’s 125,000 LCTX stock options?

The options cover 125,000 common shares at an exercise price of $1.30 per share. They expire on July 1, 2036, giving a long exercise window once vested, subject to the specified service-based vesting conditions.

When do Russell Angus’s Lineage Cell Therapeutics stock options vest?

They vest and become exercisable on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual shareholder meeting. Vesting in either case requires his continuous service with the company through that vesting date.

Is the Russell Angus Form 4 for LCTX a stock purchase or a grant?

It is a grant of stock options, not an open-market stock purchase. The transaction code is a grant or award acquisition, with zero dollar grant price and a separate $1.30 per share exercise price for future potential share acquisitions.

How many Lineage Cell Therapeutics options does Russell Angus hold from this award after the transaction?

Following this transaction, he holds 125,000 stock options from this grant. These options relate to 125,000 underlying common shares and remain subject to vesting and future exercise at the stated $1.30 per share exercise price.